Cancer Cachexia Clinical Trial
Official title:
A Phase 1, Randomized, Double-Blind, Dose-Ranging, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics Effects of OC514 in Healthy Adult Volunteers
Oncocross is developing OC514, a drug-drug combination product containing 2 active pharmaceutical ingredients for cancer cachexia. This study is designed to assess the safety and tolerability of single and multiple oral doses of OC514 in healthy adult volunteers.
This is a single-center study in which a total of 24 subjects will be enrolled into 1 of 3 dose level cohorts in an ascending fashion. Each cohort will consist of 8 subjects randomized to receive OC514 or matching placebo at a ratio of 3:1. Eligible subjects will be admitted to the clinical research unit (CRU) from Day -1 to 5 and again from Day 15 to Day 17 and will be discharged upon completion of post-dose assessment. The subjects will attend the CRU for outpatients visits on Day 8 and Day 12. The subjects will return for a follow-up visit on Day 19 and End of Study visit on Day 21. The total study duration is up to 9 weeks consisting of up to 6 weeks of screening, 2 weeks of blinded treatment, and 1 week of safety follow-up. Safety oversight will be provided by a Safety Review Committee (SRC). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT02553187 -
A Prospective, Randomized, Controlled, Multicenter Study of Kanglaite Injection for the Treatment of Cancer Cachexia
|
Phase 4 | |
| Recruiting |
NCT02848807 -
Chemotherapy-related Toxicity, Nutritional Status and Quality of Life
|
N/A | |
| Active, not recruiting |
NCT01206335 -
Open Label Study With OHR/AVR118 in Advanced Cancer Patients With Anorexia-Cachexia
|
Phase 2 | |
| Completed |
NCT00378131 -
Placebo Controlled, Randomized Safety and Efficacy Study of RC-1291 in Cancer Anorexia/Cachexia
|
Phase 2 | |
| Completed |
NCT02359123 -
Cannabics Capsules as Treatment to Improve Cancer Related CACS in Advanced Cancer Patients
|
N/A | |
| Completed |
NCT00267358 -
Placebo Controlled, Randomized Safety and Efficacy Study of RC-1291 in Cancer Anorexia/Cachexia.
|
Phase 2 | |
| Completed |
NCT03144128 -
Vitamin D for Muscle Metabolic Function in Cancer Cachexia
|
N/A | |
| Completed |
NCT01614990 -
Pilot Clinical Trial of Repeated Doses of Macimorelin to Assess Safety and Efficacy in Patients With Cancer Cachexia
|
Phase 2 | |
| Recruiting |
NCT04065815 -
Protein-rich Nutritional Therapy Combined With Time-efficient Exercise in Cancer Therapy
|
N/A | |
| Recruiting |
NCT04067167 -
Flexi Band Resistance Training Versus EMS Exercise in Patients With the Diagnosis of Malignant Diseases
|
N/A | |
| Active, not recruiting |
NCT03851133 -
Florida Pancreas Collaborative Next Generation Biobank
|
||
| Recruiting |
NCT04127981 -
Medical Imaging of Cachexia
|
N/A | |
| Not yet recruiting |
NCT05262192 -
Nutrition Education and Quality of Life in Cancer Cachexia
|
N/A | |
| Completed |
NCT04153019 -
PSYCHO-EDUCATIONAL AND REHABILITATIVE INTERVENTION FOR CANCER CACHEXIA (PRICC)
|
N/A | |
| Terminated |
NCT02066363 -
Study of Parenteral Nutrition to Patients With Gastrointestinal Cancer
|
N/A | |
| Terminated |
NCT01505764 -
The Role of Ghrelin in Cancer Cachexia
|
Phase 2 | |
| Completed |
NCT00219817 -
Safety and Efficacy of RC-1291 HCl in Patients With Cancer Related Anorexia and Weight Loss
|
Phase 2 | |
| Completed |
NCT00094562 -
A Fish Oil Supplement to Maintain Body Weight in Patients With Disease-Related Weight Loss
|
Phase 2 | |
| Recruiting |
NCT04131478 -
Effect of Gene Polymorphisms on the Pathogenesis of Cancer Cachexia
|
||
| Recruiting |
NCT05915325 -
Physical Training for Elderly Cancer Patients With Cachexia
|
N/A |